The claims, “Promotes gastrointestinal health in physically active adults” and “Helps reduce the incidence of cold-like symptoms in adults with exercise-induced stress,” have been approved for Lallemand Health Solutions’ Lactobacillus helveticus Lafti L10 strain for active adults.
Lallemand Health Solutions (Montreal) announced that Health Canada has approved two new health claims for active adults for its Lactobacillus helveticus probiotic strain, Lafti 10. The claims, “Promotes gastrointestinal health in physically active adults” and “Helps reduce the incidence of cold-like symptoms in adults with exercise-induced stress,” are now available for Lafti L10.
According to the company, Lafti L10 is “the first clinically tested probiotic strain demonstrating support for athletes’ immune health.” The company said that Lafti L10’s immune-health benefits are supported by results from four clinical studies, as well as several in vitro and in vivo mechanistic studies. In a 2016 study1 published in Applied Physiology, Nutrition, and Metabolism, Lafti L10 significantly reduced the duration of upper respiratory tract illness in elite athletes by 3.4 days.
The market for probiotics in sports nutrition is on the rise, said Lallemand in a press release. Sports nutrition is an especially promising category for probiotics because, it said, athletes are an ideal model for studying the effects of probiotics on the body’s natural defenses.
1. Michalickova D et al., “Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial,” Applied Physiology, Nutrition, and Metabolism, vol. 41, no. 7 (July 2016): 782-789